ARC101 in Advanced Solid Tumors
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.
Advanced Solid Tumor
DRUG: ARC101
Frequency and type of dose-limiting toxicities., Day 1-Day 21 of the first treatment cycle|Occurrence and severity of adverse events, serious adverse events and laboratory values., Day 1 to 100 days after the last dose of study drug.
PK Assessment: Cmax of ARC101, Measurement of Maximum Observed Concentration, During the intervention/study therapy administration, approximately 1 year on average.|PK Assessment: Cmin of ARC101, Measurement of Minimum Observed Concentration, During the intervention/study therapy administration, approximately 1 year on average.|PK Assessment: Tmax of ARC101, Measurement of Time to Reach Maximum Concentration, During the intervention/study therapy administration, approximately 1 year on average.|PK Assessment: AUC of ARC101, Area under the plasma concentration versus time curve, During the intervention/study therapy administration, approximately 1 year on average.|Overall Response Rate, Percentage of participants with best overall response of complete response (CR) or partial response (PR) according to RECIST 1.1 and overall survival (OS), During the intervention/study therapy administration, approximately 1 year on average.|Duration of Response, Time from first objective response to disease progression per RECIST 1.1 or death to any cause, During the intervention/study therapy administration, approximately 1 year on average.|Progression-Free Survival, PFS is defined as the time from the start of the treatment until objective disease progression per PFS is defined as the time from the start of the treatment until objective disease progression per RECIST 1.1 or death from any cause, During the intervention/study therapy administration, approximately 1 year on average.|Number of anti-drug antibody (ADA) Positive Participants, Immunogenicity will be measured by the number of participants that are ADA positive., During the intervention/study therapy administration, approximately 1 year on average.
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ARC101 in patients with advanced cancer.